Table 3.
Trial (NCT identifier) | Population (estimated enrollment) | Intervention | Comparator | Primary outcome | Estimated completion |
---|---|---|---|---|---|
COVACTA (NCT04320615) | Hospitalized adults with COVID-19 with SPO2 ≤ 93% or PaO2/FiO2 < 300 mg (n = 330) | TCZ 8 mg/kg IV up to 800 mg x 1 dose (additional dose may be given if symptoms worsen/no improvement shown) | Placebo | Clinical status assessed using a 7-category ordinal scale at day 28 | September 30, 2021 |
Abbreviations: IV: intravenous; PaO2/FiO2: ratio of arterial oxygen pressure to fractional inspired oxygen; SPO2: oxygen saturation; TCZ: tocilizumab.